BMS-Hengrui signs up-to-$15.2B 13-program deal; Roche pTau217 wins EU CE mark

Bristol Myers Squibb signed a global licensing and co-development agreement on May 12 with China's Hengrui for 13 early-stage oncology, hematology, and immunology programs. The package includes a $600M upfront payment, up to $950M in near-term payments, and a total potential value of $15.2B including milestones and royalties. Hengrui's Hong Kong-listed shares jumped more than 13%. The same day, Roche said its Elecsys plasma pTau217 Alzheimer's test, co-developed with Eli Lilly, received the EU CE mark ahead of a planned July 2026 launch. Lilly also overtook Novo Nordisk in non-U.S. GLP-1 share as overseas Mounjaro revenue reached $87M.